Altimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health

Core Insights - Altimmune, Inc. (NASDAQ: ALT) is advancing its lead drug candidate, Pemvidutide (ALT-801), which shows significant potential as a treatment for obesity and metabolic-associated liver disease (MASLD/MASH) [1] Group 1 - The drug candidate Pemvidutide is positioned as a comprehensive treatment option for obesity and MASLD/MASH [1] - The analysis highlights the promising nature of Pemvidutide's mechanism, which involves GLP1/glucagon pathways [1]